U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07386158) titled 'Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC' on Jan. 28.
Brief Summary: Through the neoadjuvant treatment with a combination of Pucotenlimab and Vorolanib, it enabled the successful and safe implementation of partial nephrectomy in patients with localized renal cancer, who had indications for nephron-sparing surgery but faced considerable difficulty in preserving the kidney (T1b with an endophytic component >=75% or T2)
Study Start Date: July 10, 2025
Study Type: INTERVENTIONAL
Condition:
Vorolanib
Clear Cell Renal Cell Carcinoma (ccRCC)
Neoadjuvant Therapy
Intervention:
DRUG: Pucotenlimab combinati...